Clinical trial
FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial…
NCT00424866 · CardioVascular BioTherapeutics, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00424866 |
|---|---|
| Title | FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease |
| Official title | A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication |
| Lead sponsor | CardioVascular BioTherapeutics, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral Arterial Disease, Stenosis, Intermittent Claudication |
| Intervention type | Drug |
| Interventions | FGF-1, Placebo |
| Enrollment | 24 |
| Start date | Dec 1, 2020 |
| Primary completion | Dec 1, 2021 |
| Completion | Jun 1, 2022 |
| First posted | Jan 22, 2007 |
| Last update posted | Nov 1, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: